

The eleven weeks of inaction and 32 deals that cost Australia the vaccine race

Australia lost the race in an eleven-week period from early June to mid-August during which other countries and global organisations disclosed 32 deals worth over US\$10 billion for in excess of 5 billion doses of investigative candidates – yet this is almost certainly understated because over half the deals did not disclose financial or other terms

June	July	August
US\$1.45bn in deals for 1.7bn doses	US\$6.8bn in deals for 1.4bn doses	US\$1.8bn in deals for 2.1bn doses
2 June – Australia \$2m for UQ		
<p>CEPI US\$383m 300m doses AZ-oxford</p> <p>Serum Institute of India – 1bn doses AZ-Oxford*</p> <p>US DoD US\$60m for 10m doses Novavax</p> <p>CEPI extends relationship with UQ</p> <p>Europe's IVA US\$885m 400m of AZ-Oxford</p> <p>Catalent to 'fill and finish' AZ-Oxford*</p> <p>Catalent to 'fill and finish' Moderna*</p>	<p>CEPI US\$66m Clover Biopharmaceuticals</p> <p>US US\$1.6bn 100m doses Novavax</p> <p>UK 30 million doses Pfizer-BioNTech*</p> <p>Korean SK Bioscience produce AZ-Oxford*</p> <p>US US\$1.95bn 600m doses Pfizer-BioNTech</p> <p>US US\$472 million Moderna</p> <p>UK US\$650m 60m doses Sanofi-GSK</p> <p>Japan 120m doses Pfizer-BioNTech*</p> <p>US US\$2.1bn 100m doses Sanofi-GSK</p> <p>EU 300m doses Sanofi-GSK*</p>	<p>Wockhardt deal UK to produce AZ-Oxford*</p> <p>BioKangtai manufacture AZ-Oxford in China*</p> <p>Serum Institute of India – 1bn doses Novavax*</p> <p>Switzerland 4.5m doses Moderna*</p> <p>Takeda manufacture Novavax in Japan*</p> <p>Brazil US\$356m 100m doses Moderna</p> <p>US US\$1.5bn 100m doses Moderna</p> <p>Korean SK Bioscience produce antigen Novavax*</p> <p>Indonesian PT Bio Farma to produce Sinovac*</p> <p>EU 200m doses J&J*</p> <p>EU 400m doses AZ-Oxford*</p> <p>Argentina-Mexico 250m doses AZ-Oxford*</p> <p>UK 60m doses Novavax*</p> <p>UK 30m doses J&J - option for 22m more</p>
		18 August – Australia-AZ 'letter of intent'

* Financial and other terms undisclosed